FDA expands Jazz's Ziihera use to frontline gastric cancer
read at Endpoints ↗ApprovalPositive
FDA granted approval for Jazz Pharmaceuticals' bispecific antibody Ziihera as a frontline treatment for certain gastric cancer patients.
This is the first time Ziihera will be marketed to newly diagnosed patients, expanding beyond its 2024 indication for a narrower patient group.
The label expansion could broaden the drug's market and offers an additional therapeutic option for clinicians treating gastric cancer.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA approves Jazz's Ziihera in frontline gastric cancer”
read at Endpoints ↗79 words · retrieved Aug 25
comments(0)
5-min edit window · permanent after that